ExCellThera is an advanced clinical stage biotechnology company focused on delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use.

The Situation:
Stem cell transplantation (usually from bone marrow, peripheral blood or umbilical cord blood), also known as Hematopoietic Stem Cell Transplantation or HSCT is a medical procedure most often performed on patients with cancers of the blood or bone marrow.

The Problem: HSCT is associated with a high treatment-related mortality (TRM) in the recipient, relapse and other major complications, including graft-vs-host-disease (GvHD), all of which limits the use of HSCT in life-threatening situations.

The Solution: ExCellThera’s proprietary lead solution, ECT-001, uses the molecule UM171 and an optimized expansion culture system to expand stem and immune cells:

  • greater than 1000 times;
  • in shorter periods (7 days: 2-3x faster than competitors);
  • with reduced volumes (600 mL vs. 10-30 L for competitors);
  • at lesser cost; and
  • based on Phase I/II findings, significantly reduced TRM, relapse and GvHD.